Boehringer Ingelheim Venture Fund
Capital Type
Corporate Venture Capital
Investment Size
Undisclosed / varies by deal
Geographic Scope
Global
Return Model
Dilutive
Stage Focus
Seed to Clinical
Modality Focus
Anti-infectives, Precision antimicrobials
Overview
Corporate venture fund of Boehringer Ingelheim that explicitly includes anti-infectives / AMR as a portfolio area.
Portfolio and Signals
One of the clearest strategic corporate investors to include because the fund has an explicit anti-infectives (AMR) category and precision-antimicrobial investments.
Access and Engagement
Access is strategic and relationship-led; highly differentiated science is important.
Notable AMR Examples / Programs
Explicit anti-infectives / AMR portfolio area
Stay Updated
Stay connected so that you don't miss the latest AMR insights and updates.
